Metsera (NASDAQ:MTSR - Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.66) EPS for the quarter, Zacks reports.
Metsera Stock Down 1.8%
Shares of MTSR stock traded down $0.58 during trading hours on Friday, reaching $32.41. The stock had a trading volume of 316,440 shares, compared to its average volume of 938,141. Metsera has a twelve month low of $12.30 and a twelve month high of $47.40. The company's 50-day simple moving average is $32.44.
Hedge Funds Weigh In On Metsera
Several large investors have recently bought and sold shares of the stock. Strs Ohio acquired a new position in Metsera during the 1st quarter valued at about $76,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Metsera during the 1st quarter valued at about $248,000. Finally, Goldman Sachs Group Inc. acquired a new position in Metsera during the 1st quarter valued at about $568,000.
Analysts Set New Price Targets
A number of research analysts have commented on the stock. Wells Fargo & Company assumed coverage on shares of Metsera in a research note on Friday, June 20th. They set an "overweight" rating and a $65.00 price objective on the stock. Guggenheim raised their price target on shares of Metsera from $56.00 to $62.00 and gave the stock a "buy" rating in a research report on Tuesday, June 10th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $55.00.
Read Our Latest Analysis on MTSR
About Metsera
(
Get Free Report)
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
See Also
Before you consider Metsera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metsera wasn't on the list.
While Metsera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access